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ABSTRACT
Purpose Rho-kinase regulates activation of hepatic stellate
cells (HSC) during liver fibrosis, but the ubiquitous presence of
this kinase may hinder examination of its exact role and the
therapeutic use of inhibitors. We therefore coupled the Rho-
kinase inhibitor Y27632 to a drug carrier that binds the
mannose-6-phosphate insulin-like growth factor II (M6P/IGFII)-
receptor which is upregulated on activated HSC.
Methods Y27632 was coupled to mannose-6-phosphate
human serum albumin (M6PHSA), and in vitro experiments
were performed on primary rat HSC. Biodistribution and effect
studies were performed in an acute CCl4 model in mice.
Results Y27-conjugate remained stable in serum, while drug
was efficiently released in liver homogenates. Receptor-
blocking studies revealed that it was specifically taken up
through the M6P/IGFII-receptor on fibroblasts, and it inhibited
expression of fibrotic markers in activated HSC. In vivo, liver
drug levels were significantly higher after injection of Y27-
conjugate as compared to Y27632, and the conjugate
accumulated specifically in HSC. After acute CCl4-induced
liver injury, Y27-conjugate reduced the local activation of HSC,
whereas an equimolar dose of free drug did not.
Conclusions We conclude that specific targeting of a Rho-
kinase inhibitor to HSC leads to enhanced accumulation of the




α-SMA α-smooth muscle actin
HSC Hepatic stellate cells
M6PHSA Mannose-6-phosphate human serum albumin
M6P/IGFII-
receptor
Mannose-6-phosphate/insulin-like growth factor II
receptor
ULS™ Universal Linkage System
INTRODUCTION
Liver fibrosis is the final stage of various forms of chronic
liver diseases, such as hepatitis, metabolic disorders or those
caused by drug or alcohol abuse (1). Although some of the
underlying causes of liver fibrosis can be treated, e.g.
antiviral treatment in the case of hepatitis, at this moment
there is no clinical treatment for end-stage liver cirrhosis (2).
Liver fibrosis is one of the few diseases with an ever-
increasing incidence (3), which warrants further research
for new strategies. Due to the increasing prevalence of
obesity and diabetes, nonalcoholic steatohepatitis (NASH)
will give rise to more cases of severe liver fibrosis in the
coming years (4).
Hepatic stellate cells (HSC) play a key role in the
pathogenesis of liver fibrosis (5,6). In normal livers, they are
quiescent, vitamin A-storing cells, situated near the hep-
atocytes in the space of Disse. In chronic diseases, stimuli
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development of an activated phenotype in HSC. These cells
then become highly proliferative myofibroblast-like cells,
which have a migratory phenotype and synthesize large
amounts of extracellular matrix proteins, such as collagens
and fibronectin (5,6). Activation of HSC is thus the crucial
first step in the process that leads to the production of
excess of extracellular matrix and eventually to end-stage
liver failure in cirrhotic patients. One of the key problems
in designing effective therapies is the fact that the activation
of fibroblasts is a common feature of matrix turnover and
wound-healing in all tissues. Therefore, a cell-specific
targeted approach of this disease is required for effective
treatment.
Rho-GTPase is an important regulator of cytoskeletal
organization, migration and activation of HSC and
myofibroblasts (7,8). The effect is mediated through various
downstream mediators, of which Rho-kinase is the most
important (9–11). Inhibition of Rho-kinase by the small
molecular weight inhibitor Y27632 has previously been
shown to reduce fibrotic parameters in primary HSC (12–
16) and in several animal models of liver fibrosis (12,17,18).
Apart from these anti-fibrotic effects on myofibroblasts,
Rho-kinase inhibitors have other effects when administered
systemically, such as a decrease in vascular smooth muscle
tone (19,20), leading to an acute drop in mean arterial
pressure. This would further impair the low systemic blood
pressure seen in cirrhotic patients and thus deteriorate
vascular homeostasis. Also, other kinase inhibitors currently
in clinical use have been shown to cause side effects during
treatment, which were not found during pre-clinical and
clinical trials (20). In order to avoid these adverse effects
and improve the effects of the Rho-kinase inhibitor, we
coupled Y27632 to stellate-cell specific carrier mannose-6-
phosphate human serum albumin (M6PHSA). This carrier
is specifically taken up by HSC through the mannose-6-
phosphate insulin-like growth factor II (M6P/IGFII)-recep-
tor (21), which is highly and specifically upregulated on
activated HSC during liver fibrosis (22,23). This multifunc-
tional receptor traffics between the Golgi and the
endosomal-lysosomal network and also shuttles to the
plasma membrane (24). After binding, the protein-
receptor complex is taken up into the cell through
endocytosis (21). The Y27-conjugate will therefore be
targeted to the liver and taken up specifically in HSC,
increasing the drug dose in the target cell, whilst lowering it
in non-target cells, thus reducing the chance of side effects.
In the present study, we aimed to examine the feasibility
of targeting the Rho-kinase inhibitor Y27632 to the key
cells in fibrogenesis, the HSC. We prepared the construct
Y27632-M6PHSA and tested it in vitro in primary HSC and
in vivo in an acute mouse model of CCl4-induced liver
injury, characterized by local HSC activation. Biodistribu-
tion and effect studies show that the targeted Rho-kinase
inhibitor is effectively delivered to the HSC, leading to high
local drug concentrations within the liver, and locally
reduces fibrotic parameters in vivo.
MATERIALS AND METHODS
Materials
Y27632 was purchased from Tocris Bioscience (Bristol,
UK). Primary antibodies used were mouse anti-α-smooth
muscle actin and anti-desmin (Sigma, St.Louis, MO),
rabbit anti-human serum albumin (Cappel, Zoetermeer,
Netherlands) and goat anti-M6P/IGFII-receptor (Santa
C r u zB i o t e c h n o l o g y ,S a n t aC r u z ,C A ) .S p e c i e s - s p e c i f i c
HRP or AP-coupled secondary antibodies were pur-
chased from DAKO (Glostrup, Denmark).
Synthesis of Y27632-ULS-M6PHSA
The Universal Linkage System (ULS™)—developed by
Kreatech Diagnostics, Amsterdam, The Netherlands—is a
platinum-based linkage technology which facilitates the
coupling of molecules directly to each other through the
formation of a coordinative bond. The ULS™ technology
has been proven to have important applications in the areas
of genomics, proteomics, diagnostics, and therapeutics. The
linker was conjugated to Y27632 as previously reported
(25). M6P28HSA was synthesized and characterized as
described elsewhere (26). ULS-Y27632 (2.1 μmol) was
subsequently reacted with M6PHSA (0.14 μmol) in
20 mM tricine buffer (pH 8.5) at 37°C, and the resulting
conjugate was extensively dialyzed against PBS at 4°C and
purified by size-exclusion chromatography using a Super-
dex 200 column on an Äkta System (GE Healthcare,
Uppsala, Sweden) to isolate the monomeric form of the
drug-protein conjugate.
Characterization of Y27632-ULS-M6PHSA
The amount of Y27632 coupled to M6PHSA was deter-
mined by HPLC analysis after chemically displacing the
drug from the carrier by incubation with 0.5 M potassium
thiocyanate (KSCN) at 80°C. M6PHSA protein concen-
tration was determined by Lowry assay (Bio-Rad, Hercules,
CA). The release of drug from the Y27632-M6PHSA
conjugate was determined after incubation in PBS, serum
or liver homogenate until 24 h at 37°C and after 1 to 2
freeze-thaw cycles. Extraction of the Y27632 released from
the carrier was performed as reported previously (25).
HPLC analysis was performed on a C18 reversed-phase
SunFire column (Waters, Milford, MA) using a mobile
2046 van Beuge et al.phase of water-methanol-trifluoroacetic acid (86:14:0.1,
vol/vol/vol; pH 2.0) at a flow-rate of 1 ml/min. Y27632
was detected at 270 nm and eluted after circa 6.0 min.
Quantitation of the drug was performed by analyzing peak
areas using calibration curves prepared in the same media.
The Y27-conjugate was further analyzed by size-
exclusion chromatography and anion exchange chroma-
tography as described before (21).
In Vitro Assays
NIH-3T3 fibroblasts were cultured in DMEM (Lonza,
Verviers, Belgium) containing 10% fetal calf serum (FCS)
and penicillin/streptomycin. For binding studies, cells were
incubated 2 h with 0.1 mg/ml Y27-conjugate or control,
where necessary, preceded by a pre-incubation with M6P/
IGFII-receptor antibody for 30 min.
Primary HSC were isolated from livers of male Wistar
rats (>500 g, Harlan, Netherlands) according to previously
published methods (27). After isolation, HSC were cultured
on plastic for 10 days until activation and then used for
experiments.
Real-Time PCR
Total RNA was isolated from HSC using the Absolutely
RNA Microprep Kit (Stratagene, La Jolla, CA). The
amount of RNA was determined using a NanoDrop
UV-detector (NanoDrop Technologies, Wilmington,
DE). Synthesis of cDNA was performed using the
Superscript III first-strand synthesis kit (Invitrogen,
Carlsbad, CA) with random primers. All primers for
real-time quantitative PCR (Supplementary Table 1)
were purchased from Sigma Genosys (Haverhill, UK).
Gene expression levels were measured by real-time
quantitative PCR on an ABI 7900HT apparatus (Applied
Biosystems, Foster City, CA) with SYBR-Green PCR
Master Mix (Applied Biosystems). The formation of single
products was confirmed by analyzing the dissociation step
at the end of each PCR reaction. Data were analyzed
using the SDS 2.3 software program (Applied Biosys-
tems). The relative amount of product was calculated
using the ΔΔCt method, normalizing for the expression of
the household gene GAPDH and related to the control
treatment.
Animal Experiments
All animal experiments were approved by the Animal
Ethics Committee of the University of Groningen, the
Netherlands. All animals were purchased from Harlan
(Zeist, Netherlands) and kept at 12 h light/12 h dark cycles
with ad libitum chow and water.
CCl4-Induced Acute Liver Injury
For in vivo studies in the acute (72 h) model, male C57/Bl6
mice (20–22 g) received a single intraperitoneal injection of
1 ml/kg CCl4 diluted in olive oil. Control mice received
olive oil. The mice were divided into 5 groups: 1) control
+vehicle (PBS), 2) CCl4+vehicle (PBS), 3) CCl4+Y27632-
M6PHSA (equivalent to 1.5 mg/kg/day Y27632 and
45 mg/kg/day M6PHSA), 4) CCl4+Y27632 (1.5 mg/kg/
day), 5) CCl4+M6PHSA (45 mg/kg/day). All treatment
groups received two i.v. injections at 24 and 48 h after CCl4
and were sacrificed 24 h after the last injection.
For biodistribution studies mice received a single i.v.
injection of Y27-conjugate or Y27632 at 24 h after CCl4
injection. At 15 min, 30 min, 60 min, 3, 6, 24 and 48 h after
i.v. injection of the compounds, mice were sacrificed (two
mice per time-point), and liver and blood samples were
collected for determination of drug levels through HPLC.
Fifty mg of liver tissue was homogenized in 1:10 (w/v) PBS,
whereas plasma (40 μl) was diluted 1:5 in PBS. The samples
were extracted as described above to determine the levels of
free drug. For the total conjugate-associated drug levels,
samples were incubated overnight with 0.5 M KSCN at 80°C
and then extracted as described above.
Immunohistochemistry
Immunohistochemistry was performed on 4 μm cryostat or
paraffin sections. Periodic acid-Schiff’s (PAS) staining was
p e r f o r m e do n4μm paraffin sections. Stainings were
visualized using 3, 3′-diamino-benzidine tetrahydrochloride
or 3-amino-9-ethylcarbazole. Nuclei were counterstained
with Mayer’s hematoxylin. Immunohistochemical stainings
were quantitated using the Cell D computer program
(Olympus, Hamburg, Germany).
Statistical Analysis
Results are expressed as the mean ± SD, unless otherwise
specified. Statistical analyses were performed using Stu-
dent’s t test or one-way ANOVA with post-hoc Bonferroni
test. p<0.05 was considered as the minimum level of
significance.
RESULTS
Synthesis and Characteristics of Y27-Conjugate
To create an HSC-specific conjugate, we coupled the Rho-
kinase inhibitor Y27632 to M6PHSA using the Universal
Linker System (ULS™). M6PHSA was previously found to
bind specifically to the M6P/IGFII-receptor which is
Stellate Cell-Specific Delivery of a Rho-kinase Inhibitor 2047abundantly present on activated HSC (21). The applied
ULS-based method allows coupling of the aromatic
nitrogen with sp2 hybridization in the pyridine ring, a
common functional group in many kinase inhibitors (28), to
the histidine and methionine groups of the protein (Fig. 1a).
Subsequently, the conjugate was characterized using anion
exchange chromatography. Introduction of Y27-ULS
groups shifted the peak left compared to M6PHSA
(Fig. 1b), due to addition of positive charge provided by
the amine group in Y27632, confirming the coupling of
Y27-ULS to the carrier. However, the resulting conjugate
still retains an overall negative charge, since the Y27-ULS
groups do not fully neutralize the negative charge intro-
duced by 28 M6P groups. Size-exclusion chromatography
showed that after purification approximately 90% of the
Y27-conjugate was in the monomeric form (Fig. 1c).
The average molar coupling ratio of drug to M6PHSA was
7:1. HPLC analyses showed that there was no free drug
present in the final product. We subsequently analyzed the
drug release properties of the conjugate in biological media
and found that only 2% or 6%, respectively, of Y27632 was
released in physiological buffer and in serum at 37°C within
24 h. In contrast, in liver homogenates approximately 40% of
the coupled Y27632 was released (Fig. 1d), demonstrating that
Y27632 can be released from the carrier within the liver,
without premature release in serum.
Binding of the conjugate to the target receptor was
examined in 3T3 fibroblasts, which express the M6P/IGFII
receptor (Fig. 2a). Using anti-HSA staining, we found that
Y27-conjugate bound to the cells (Fig. 2b), while unmod-
ified HSA did not bind (26). Importantly, the binding was
strongly inhibited by pre-incubating the cells with an M6P/
IGFII-receptor specific antibody (Fig. 2b). These data
demonstrate that the conjugate binds specifically to the
designated target receptor.
Y27-Conjugate Inhibits Fibrotic Parameters in
Activated HSC
To assess the effects of free Y27632 and Y27-conjugate on
activated HSC, we analyzed mRNA expression for α-
smooth muscle actin (α-SMA) in cultures of primary
isolated HSC. α-SMA is the key marker reflecting the
transformation of quiescent HSC into an activated,
contractile phenotype (29), which starts to occur spontane-
ously in primary HSC after at least three days of cultivation
in vitro. Additionally, we analyzed TIMP-1, which is also
upregulated in activated HSC and inhibits breakdown of
extracellular matrix (30). We found that the Y27-conjugate
significantly reduced the expression of α-SMA and TIMP-1
(Fig. 3) in activated HSC. Effects of the targeted Rho-kinase
inhibitor were similar to the effects of the untargeted
inhibitor. The effects were not due to cell death, as there
was no effect on cell viability, as measured by alamar blue
conversion through mitochondrial activity (results not
shown).
In Vivo Biodistribution of Y27-Conjugate
The biodistribution of the targeted conjugate was
compared to that of the free drug in animals with
CCl4-induced liver fibrosis 60 min after i.v. injection of
Fig. 1 Characteristics of the
Y27632-ULS-M6PHSA conjugate.
(a) Structure and diagram of the
synthesis of the Y27632-ULS-
mannose-6-phosphate conjugate.
(b) Results of the anion exchange
chromatography of HSA,
M6PHSA and Y27-conjugate. (c)
Results of size exclusion chroma-
tography of Y27-conjugate. (d)
Y27632 release from the conju-
gate at different time-points up to
24 h in PBS, liver homogenate
and serum at 37°C. Collectively
the data show that the Y27-
conjugate has a reduced negative
charge and increased molecular
weight compared to M6PHSA.
Significant release of drug from the
carrier only occurs in liver homo-
genates.
2048 van Beuge et al.the conjugate. In these livers M6P/IGFII receptor
expression was already upregulated compared to control
animals (Fig. 4a). No positive staining for M6P/IGFII
receptor could be detected in other organs (spleen, heart,
kidney or lung), neither in control nor CCl4-treated
animals. The conjugate was detected using anti-HSA
staining, which was found only in fibrotic livers treated
with Y27-conjugate, whereas at the same time-point, no
staining could be detected in the heart, kidney or lung,
and only weak staining was present in the spleen (Fig. 4a).
Administration of normal unmodified HSA did not result
in any organ-specific staining (data not shown). Double-
staining with HSC-marker desmin within the liver showed
that the intrahepatic staining for the conjugate (blue) co-
localized with staining for desmin (red) (Fig. 4b), confirm-
ing uptake in the target cells within the liver.
Drug levels were also measured within these livers using
an HPLC method. Low levels (1–2 μg/g tissue) of free drug
could be detected in the livers only up to 3 h after i.v.
injection of free Y27632 (Fig. 5a). In contrast, after
injection of an equimolar dose of the conjugate, signifi-
cantly higher levels (up to 15 μg/g tissue) of carrier-bound
drug were found in the livers up to 48 h. We also
determined the amount of free drug released from the
conjugate in the livers after injection of the conjugate and
found a slow and prolonged local release of the free drug at
least up to 48 h after a single injection (Fig. 5a).
Daily dosing led to a build-up of the drug concentration
in fibrotic livers: while one injection led to a drug
concentration of 10 μg/g liver, three injections with 24 h
time intervals led to a concentration of 25 μg/g liver
(Fig. 5b). These data indicate that Y27-conjugate remains
Fig. 2 Binding of Y27-conjugate to M6P/IGFII-receptor. (a) Expression of the M6P/IGFII-receptor on NIH-3T3 fibroblasts. Left: control, right: M6P/IGFII-
receptor staining. Original magnification 20×. (b) HSA staining showing the binding of Y27-conjugate to fibroblasts: control cells (left), conjugate-incubated
cells (middle), and conjugate-incubated cells pretreated with a M6P/IGFII receptor-specific antibody (right). Note that blocking of the receptor with an
antibody reduces the binding of the conjugate to the cells. Original magnification 20×.
Fig. 3 Y27-conjugate inhibits ac-
tivation of hepatic stellate cells.
Effect of Y27-conjugate on the
mRNA levels of fibrotic markers
α-SMA and TIMP-1 in isolated rat
HSC after 48 h incubation with
10 μM of Y27-conjugate or
equivalent amounts of Y27632 or
carrier. * p<0.05 vs. control, **
p<0.01 vs. control, *** p<0.001
vs. control by Student’s t-test.
Stellate Cell-Specific Delivery of a Rho-kinase Inhibitor 2049in the liver after injection for more than 24 h and that free
drug is slowly released, in accordance with the data
presented in Fig. 5a.
In addition to liver biodistribution, we also examined
distribution of the Y27-conjugate in plasma. The
conjugate-bound drug could be detected in plasma up to
3 h after injection, whereas the free drug could only be
detected up to 15 min after injection (Fig. 5c).
The Y27-Conjugate Reduces Rho-kinase Signaling
and HSC Activation In Vivo
Livers of CCl4-treated mice showed a strong, localized
upregulation of α-SMA in the central areas damaged by
CCl4, representing activated, pro-fibrotic HSC. Treatment
with Y27-conjugate significantly reduced α-SMA staining,
indicating inhibition of HSC activation (Fig. 6a), while
untargeted Y27632 did not inhibit α-SMA staining in these
areas at all (Fig. 6b). The Y27-conjugate did not affect the
total number of HSC in the livers, as the amount of desmin
staining, reflecting both activated and unactivated HSC, was
not changed significantly after treatment (Fig. 6c). These
data show that the Y27-conjugate accumulated in activated
HSC, thereby reducing their activity but not their number.
DISCUSSION
In this study, we have shown that HSC-targeted delivery of
a Rho-kinase inhibitor is possible: Y27632 coupled to
M6PHSA strongly accumulated in the liver, and immuno-
histochemical studies showed uptake of the construct in
particular in the desmin-positive cells, reflecting accumula-
tion in HSC. Y27632 was not released in serum, so staining
Fig. 4 Intrahepatic localization of Y27-conjugate. (a) Upper panel: Representative photomicrographs of M6P/IGFII-receptor staining (red) in spleen, heart,
kidney, lung and liver of control and CCl4-treated mice. Lower panel: Representative photomicrographs of HSA staining (red) in spleen, heart, kidney, lung
and liver of CCl4-mice treated with PBS (control) and Y27-conjugate 1 h before sacrifice. Original magnification 20×. (b) Y27-conjugate localization in liver
as determined by double staining for HSA (blue) and the HSC marker desmin (red) in mouse livers 1 h after injection of Y27-conjugate in CCl4-treated
mice. Original magnification 40×.
2050 van Beuge et al.for the conjugate in desmin-positive HSC, 1 h after its
administration, reflects uptake of the drug in this cell type.
Rho-kinase inhibitors have been used before in rat
models of liver fibrosis, and these studies have shown anti-
fibrotic effects of the inhibitors (12,17,18). However, in
these studies, doses of 30 mg/kg of drugs were routinely
used. Cell-specific delivery of Rho-kinase inhibitor may
lead to a lower dose regimen. Indeed, we now have used
doses of 1.5 mg/kg drug in this study and established strong
pharmacological effects. We are thus able to reduce the
dose needed to obtain a significant effect, while this lower
dose is specifically delivered to the target cells, increasing
the concentration in the target cell compared to the
concentration reached after systemic administration of free
drug. This results in a two-pronged approach to avoid off-
target effects and increase anti-fibrotic effects of a Rho-
kinase inhibitor in the liver. Avoiding adverse effects is
relevant for the treatment of patients, since the Rho-kinase
pathway is found to play an important role in vascular
homeostasis and is deregulated in cirrhotic patients (31,32).
The Rho-kinase inhibitor was coupled to the targeted
carrier system using ULS™ conjugation technology. This
coupling method is based on coordination chemistry (33)
and offers a rapid method for the coupling of proteins to
drugs. It has been used in the past for the coupling of
various kinase inhibitors to protein carriers (33–35), in
particular when reactive groups in the drug are not
available for conventional methods of conjugation. In
addition, it provides a slow intracellular release of the drug
in its active form from the carrier molecule during several
days (34). This slow drug-release profile is particularly
relevant for the treatment of chronic diseases such as liver
fibrosis.
In vitro, the Y27632–M6PHSA conjugate was taken up
by cells via the M6P/IGFII-receptor, as indicated by
blockade of its uptake by IGFII-receptor-specific anti-
bodies. Coupling of the drug to the carrier does not affect
interaction with its target receptor. The drug was released
from the construct in a pharmacologically active form
within the target cells as reflected by a significant reduction
of HSC activation in vitro. We examined the effects of drugs
and constructs in cultures of primary HSC in order to be
able to examine the effect of Y27632 on spontaneous HSC
activation. Primary, spontaneously activated HSC are an
established in vitro model for the behavior of HSC in early
fibrosis (36) .B o t ht h ec o n j u g a t ea n dt h ef r e ed r u g
significantly inhibited the expression of the activation
markers α-SMA and TIMP-1 in primary HSC.
In vivo as well, the Y27-conjugate attenuated α-SMA
expression, confirming that Rho-kinase activity is involved
in the transformation of HSC from a quiescent into an
activated phenotype with contractile capabilities. Reduction
of α-SMA by the Rho-kinase inhibitor is well-known
(12,17,18) and might also be achieved via a direct effect
of Rho-kinase on the α-SMA promotor (37). Neither the
Y27-conjugate nor the free drug had any significant effect
on the total number of HSC in the livers of CCl4-treated
mice. In the past, several groups have looked into the effect
Fig. 5 Drug concentrations in
vivo and release of Y27632 from
the carrier. Drug concentrations in
livers after i.v. administration of
Y27632 or Y27-conjugate to
CCl4-mice. (a) HPLC analysis of
liver extracts of CCl4-treated mice
showing the biodistribution of
Y27-conjugate vs. free Y27632 in
livers up to 48 h after injection. (b)
Accumulation of Y27-conjugate in
livers of CCl4-treated mice,
10 min after injection (1 injection)
and after 3 injections, 48 h, 24 h
and 10 min before sacrifice (3
injections). (c) HPLC analysis of
plasma of CCl4-treated mice
showing the biodistribution of
Y27-conjugate vs. free Y27632 in
plasma up to 6 h after i.v. injec-
tion. Note that free Y27632 is
only found in plasma at t=15 min
in low amounts.
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fibroblasts. Different studies found either a pro-apoptotic
effect or no effect at all (15,38,39). We have also examined
this effect of the Rho-kinase inhibitor. In this study, neither
the free drug nor the conjugate affected HSC viability in
vitro (data not shown) or in vivo, measured as the amount of
desmin-positive cells.
Importantly, administration of the HSC-targeted Rho-
kinase inhibitor led to a stronger reduction of HSC
activation, as reflected by a reduced α-SMA staining, than
systemic treatment with the free Rho-kinase inhibitor. This
shows the strength of our targeted approach, in accordance
with previous papers examining cell-specific inhibition of
fibrosis-related pathways in HSC using other drugs
(35,40,41). Our biodistribution studies, showing elevated
levels of the drug within the liver after treatment with the
conjugate and a prolonged residence time of conjugate-
associated drug, also are consistent with these stronger
effects in the liver.
Drug concentrations in whole livers of mice receiving the
targeted Rho-kinase inhibitor were much higher than in
mice receiving the free drug, and concentrations remained
high for a prolonged period of time. Based on the
immunohistochemical data, it can be deduced that these
high drug levels were concentrated in HSC, whereas the
low liver uptake of free Y27632 reflects uptake by different
cell-types, most likely the hepatocyte, since these cells are
equipped to take up xenobiotics. Earlier studies from our
group have shown that M6PHSA is rapidly endocytosed
and degraded by the target cells, thus favoring intracellular
drug release (26). In previous studies using this combination
of carrier and linker in vivo (40,41), we also found a
pharmacokinetic profile characterized by high uptake of the
conjugate in the liver and a slow release of free drug. Both
distribution and degree of uptake of M6PHSA found in the
present study were similar to these previous chronic studies.
In conclusion, we report here the cell-specific delivery of
a conjugate containing a Rho-kinase inhibitor to the M6P/
IGFII-receptor on activated HSC. A cell-specific drug-
conjugate needs to be evaluated on several important
aspects. Accordingly, we present here data on the stability
of the conjugate in plasma, release of the pharmacologically
Fig. 6 Y27-conjugate reduces HSC activation in acute CCl4-induced liver injury. (a) Representative pictures of immunohistochemical staining for α-SMA
on liver sections of mice, 72 h after one injection of CCl4 (or olive oil in control) and treated with vehicle (PBS), Y27-conjugate, Y27632 or carrier at t=
24 and 48 h. (b) Quantitation of the area stained positive for α-SMA relative to the area stained positive in control CCl4 sections. Stainings were
quantitated using the Cell D computer program, calculating the total stained area in 18–24 fields per section at 20× magnification as a percentage of the
stained area in the control CCl4 sections. Data shown are the mean of 6 animals per group. * p<0.05 vs. CCl4-PBS by one way ANOVA with Bonferroni
post-hoc test. (c) Quantitation of the relative area stained positive for desmin. Stainings were quantitated at 10× magnification using the Cell D computer
program as described above. Data shown are the mean of 6 animals per group.
2052 van Beuge et al.active compound in target cells and receptor-specific uptake
of the conjugate. In vivo we found a pharmacokinetic profile
with prolonged high drug levels in liver and localization of
the conjugate within HSC, the key cells during fibrogenesis.
The targeted Rho-kinase inhibitor reduced fibrotic para-
meters in vivo more effectively than the free drug. Our study
shows the feasibility of a cell-specific delivery of kinase
inhibitors, which represent an important group of new
chemical entities for various serious diseases, including liver
fibrosis.
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